Literature DB >> 21067184

DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis.

Francisca Barceló1, Miguel Ortiz-Lombardía, Miquel Martorell, Miquel Oliver, Carmen Méndez, José A Salas, José Portugal.   

Abstract

The antitumor antibiotics mithramycin A and chromomycin A(3) bind reversibly to the minor groove of G/C-rich regions in DNA in the presence of dications such as Mg(2+), and their antiproliferative activity has been associated with their ability to block the binding of certain transcription factors to gene promoters. Despite their biological activity, their use as anticancer agents is limited by severe side effects. Therefore, in our pursuit of new structurally related molecules showing both lower toxicity and higher biological activity, we have examined the binding to DNA of six analogues that we have obtained by combinatorial biosynthetic procedures in the producing organisms. All these molecules bear a variety of changes in the side chain attached to C-3 of the chromophore. The spectroscopic characterization of their binding to DNA followed by the evaluation of binding parameters and associated thermodynamics revealed differences in their binding affinity. DNA binding was entropically driven, dominated by the hydrophobic transfer of every compound from solution into the minor groove of DNA. Among the analogues, mithramycin SDK and chromomycin SDK possessed the higher DNA binding affinities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21067184     DOI: 10.1021/bi101398s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Chromomycin SA analogs from a marine-derived Streptomyces sp.

Authors:  Youcai Hu; Ana Paula D M Espindola; Nathan A Stewart; Shuguang Wei; Bruce A Posner; John B MacMillan
Journal:  Bioorg Med Chem       Date:  2011-07-20       Impact factor: 3.641

2.  A rapid fluorescent indicator displacement assay and principal component/cluster data analysis for determination of ligand-nucleic acid structural selectivity.

Authors:  Rafael Del Villar-Guerra; Robert D Gray; John O Trent; Jonathan B Chaires
Journal:  Nucleic Acids Res       Date:  2018-04-20       Impact factor: 16.971

3.  A fluorescent reporter on electrostatic DNA-ligand interactions.

Authors:  Chandrashekhar U Murade; George T Shubeita
Journal:  Biomed Opt Express       Date:  2021-12-07       Impact factor: 3.732

4.  Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.

Authors:  Jeffrey Roth; Cody J Peer; Brigitte Widemann; Diane E Cole; Rachel Ershler; Lee Helman; David Schrump; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-09-06       Impact factor: 3.205

5.  A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis.

Authors:  Luz E Núñez; Stephen E Nybo; Javier González-Sabín; María Pérez; Nuria Menéndez; Alfredo F Braña; Khaled A Shaaban; Min He; Francisco Morís; José A Salas; Jürgen Rohr; Carmen Méndez
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

6.  Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.

Authors:  Anastasia Malek; Luz-Elena Núñez; Marco Magistri; Lara Brambilla; Sandra Jovic; Giuseppina M Carbone; Francisco Morís; Carlo V Catapano
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

7.  Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia.

Authors:  Lorenzo Capretto; Stefania Mazzitelli; Eleonora Brognara; Ilaria Lampronti; Dario Carugo; Martyn Hill; Xunli Zhang; Roberto Gambari; Claudio Nastruzzi
Journal:  Int J Nanomedicine       Date:  2012-01-18

8.  The crucial role of divalent metal ions in the DNA-acting efficacy and inhibition of the transcription of dimeric chromomycin A3.

Authors:  Chun-Wei Hsu; Show-Mei Chuang; Wen-Ling Wu; Ming-Hon Hou
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

9.  Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.

Authors:  Eléonore Otjacques; Marilène Binsfeld; Natacha Rocks; Silvia Blacher; Karin Vanderkerken; Agnès Noel; Yves Beguin; Didier Cataldo; Jo Caers
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  EPS8 inhibition increases cisplatin sensitivity in lung cancer cells.

Authors:  Lidija K Gorsic; Amy L Stark; Heather E Wheeler; Shan S Wong; Hae K Im; M Eileen Dolan
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.